Development of novel class of compounds for eye delivery to stop neurodegeneration in glaucoma

Summary:

A French pre-clinical stage start-up develops novel solutions to treat neurodegeneration, a process linked with microtubule disorders. It develops compounds to restore microtubule stability. One application is stopping neurodegeneration of the optic nerve in glaucoma, the leading cause of irreversible blindness. The company seeks partners specialized in biopolymers and/or surface chemistry to develop drug formulation and delivery solutions into the eye under research or technical agreements.

Reference: TRFR20190621001

Country: France

Submitted: 19. 11. 2019

View Partnering Opportunity

Keywords

Technology: Pharmaceutics; Neurology, Brain Research; Pharmaceutical Products / Drugs; Biochemistry / Biophysics; Biopolymers

Market: Biochemistry / Biophysics; Drug delivery and other equipment; Ophthalmology, ear, nose and throat diseases; Pharmaceuticals/fine chemicals

NACE: Research and experimental development on biotechnology

Technologické nabídky a poptávky zpracovává BIC Plzeň, partner sítě Enterprise Europe Network.